“We seek to do more than incrementally improve diagnostics and treatment,
but rather to invent complete and novel solutions to unmet clinical needs.”
With dozens of decades of combined expertise in spearheading diagnostic solutions, our team of medical, technology and healthcare experts is singly focused on developing innovative, patented technologies for cardiology, respiratory and other complex disease states that are uniquely designed to enhance clinical efficacy to the benefit of patients and physicians. Our medical devices and systems are created to be physician- and patient-centric, utilizing the most advanced algorithms and software that provide improvements in mean time to diagnosis and treatment.
Brad Harlow, CEO
An industry-leading executive in the field of cardiac diagnostics and medical devices, he most recently served as CEO of PhysioSonics and prior to that had senior positions with Data Critical (acquired by GE Medical) and Instromedix. Mr. Harlow is Chairman of CBC Partners, a private commercial lender, and also Managing Director of B.Harlow & Associates, LLC, a firm that has helped raise over $250 Million for cardiology and med-tech companies and provides strategic consulting to senior management.
Robert Odell, COO
With broad operating, product development, strategy and regulatory/quality experience, Mr. Odell has held executive positions at General Electric, Medtronic, Analogic Corporation and Siemens. Prior to working with Cardiac Insight, he was CEO and COO of Cardiac Science Corporation and Criticare Systems Inc., leaders in the defibrillation and patient monitoring markets.
Mike Schuh, CFO
With almost 30 years of experience in accounting and finance., Mr. Schuh was most recently (from 2000 until 2010) Vice President, Finance and Chief Financial Officer of SonoSite Inc., the pioneer and leader of point-of-care hand-carried ultrasound. During his tenure, worldwide sales grew from $10 million to $275 million and employees from 100 to 900.
Dave Hadley, PhD, Senior VP of R&D
Dr. Hadley has over 30 years of hands-on experience blending customer needs with information technology through research and development. He spent nine years as Vice President of Research and Development for Quinton Cardiology. In this role, Dr. Hadley was responsible for rebuilding the engineering team, establishing robust new product architectures and developing the next generation of Quinton and Burdick diagnostic ECG products. Prior to his role at Quinton Cardiology, Dr. Hadley was with Primus Knowledge Solutions and Sierra Geophysics. He earned his PhD from the California Institute of Technology.
Ann Demaree, VP of Marketing & Business Development
A healthcare marketing strategist and innovator, Ms. Demaree brings more than twenty-five years of medical device and healthcare IT industry consulting and commercialization experience, including marketing and corporate business development leadership roles at Welch Allyn, CapsuleTech and numerous other disruptive medical technology start-ups.
Stacy Spouse, VP of Sales
Ms. Sprouse has a broad background in sales management, marketing, and product development. Most recently, she was the Vice President of Sales and Marketing for Syncroness, Inc., an engineering services company specializing in development of medical device and aerospace products. Prior to that, she held leadership positions at Medtronic in the Neuro, Spine, and ENT groups and at Cardiac Science Corporation and Criticare Systems Inc., leaders in diagnostic cardiology, defibrillation, and patient monitoring.
Richard O. Martin, PhD, Chairman, Board of Directors
Richard O. Martin, PhD., was formerly President and Chief Executive Officer of Physio-Control International. Martin joined Physio-Control as President in 1991, when the company was part of Eli Lilly’s Medical Devices Division. Dr. Martin’s former positions include as a Vice President of SulzerMedica, Inc., and President and COO of Positron Corporation, a medical diagnostic imaging equipment company. Martin has a Ph.D. in electrical engineering from Duke University, an MSEE from Notre Dame University and a BSEE from Christian Brothers College.
Bill Willis, Business Advisor
Most recently Bill served at iRhythm Technologies Inc. (NASDAQ IRTC) as President and Chief Executive Officer. Prior to iRhythm, Mr. Willis founded iCardia Healthcare Inc., where the first “single-use” medical device technology was introduced into the U.S. market. During the past 30 years he has devoted his career specifically to the cardiac diagnostic industry. Mr. Willis has been responsible for building several of the preeminent companies in the industry today, including iRhythm Technologies Inc., CardioNet, where he served in the Office of the President, and Lifewatch, as President and Chief Executive Officer.
Scientific Advisory Board
Robert G. Hauser, MD, FACC, FHRS, Chair
Dr. Hauser, Chair of the Cardiac Insight Scientific Advisory Board, is former President of the Heart Rhythm Society, a senior consulting cardiologist at the Minneapolis Heart Institute®, and past president of the Cardiovascular Services Division at Abbott Northwestern Hospital in Minneapolis. Dr. Hauser’s major career research interest is the safety and efficacy of implantable pacemakers and defibrillators. He has published multiple papers regarding the reliability and performance of implantable cardiac rhythm management devices. Dr. Hauser is also actively engaged in innovations in arrhythmia detection, particularly atrial fibrillation, in at-risk populations.
Victor Froelicher, MD, FACC, FAHA, FACSM
A professor of medicine at Stanford University and cardiologist to Stanford University athletes, Dr. Froelicher is respected worldwide for his knowledge about cardiology, exercise, computerized electrocardiography and the cardiovascular system. Dr. Froelicher has been director of the ECG and Exercise Testing Laboratories at the Palo Alto Veterans Affairs Health Care System since 1992.Previously, he served 11 years in the U.S. Air Force and as Chief of Cardiology at the Long Beach Veterans Affairs Medical Center and principal investigator of the NIHLBI randomized trial of cardiac rehabilitation called PERFEXT.